Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Abbott Laboratories (GB:0Q15)
LSE:0Q15
Holding GB:0Q15?
Track your performance easily
0Q15 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$90.87 - $121.60
Previous Close$117.28
Volume3.58K
Average Volume (3M)14.75K
Market Cap
$204.00B
Enterprise Value$211.78B
Total Cash (Recent Filing)$7.22B
Total Debt (Recent Filing)$14.75B
Price to Earnings (P/E)37.0
Beta0.45
Next Earnings
Oct 16, 2024EPS Estimate
$1.2Last Dividend Ex-Date
Oct 15, 2024Dividend Yield1.86%
Share Statistics
EPS (TTM)3.17
Shares Outstanding1,739,897,004
10 Day Avg. Volume70
30 Day Avg. Volume14,749
Standard Deviation0.04
R-Squared0.01
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)2.52
Price to Sales (P/S)5.01
Price to Cash Flow (P/CF)26.00
P/FCF Ratio33.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.20
Enterprise Value/Gross Profit9.57
Enterprise Value/Ebitda20.44
Forecast
1Y Price Target
$129.06Price Target Upside11.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
Abbott Laboratories News
Bulls Say, Bears Say
Bulls Say
Earnings And Financial PerformanceThe company has increased its full-year guidance twice so far this year, projecting ex-COVID organic sales growth of 9.5-10.0%.
Market PositionTriClip is outpacing EW's Evoque by as much as 3:1 in competitive estimation.
Product DevelopmentThe pivotal US trial for Abbott's Volt PFA device completed enrollment slightly ahead of schedule, indicating a timely progression towards regulatory approval.
Bears Say
Financial PerformanceLight EPS guidance and stronger foreign exchange headwinds have negatively impacted the company's topline.
Legal RisksA jury in St. Louis ordered Abbott Laboratories to pay $495M in the company's first necrotizing-enterocolitis case, with the verdict amount significantly higher due to the jurisdiction allowing punitive damages.
Litigation ImpactAbbott Laboratories shares have underperformed due to ongoing NEC litigation, which has been an overhang on the stock.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.47% Insiders
24.53% Mutual Funds
0.67% Other Institutional Investors
55.56% Public Companies and
Individual Investors
0Q15 FAQ
What was Abbott Laboratories’s price range in the past 12 months?
Abbott Laboratories lowest share price was $90.87 and its highest was $121.60 in the past 12 months.
What is Abbott Laboratories’s market cap?
Currently, no data Available
When is Abbott Laboratories’s upcoming earnings report date?
Abbott Laboratories’s upcoming earnings report date is Oct 16, 2024 which is today.
How were Abbott Laboratories’s earnings last quarter?
Abbott Laboratories released its earnings results on Jul 18, 2024. The company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $1.105 by $0.035.
Is Abbott Laboratories overvalued?
According to Wall Street analysts Abbott Laboratories’s price is currently Undervalued.
Does Abbott Laboratories pay dividends?
Abbott Laboratories pays a Quarterly dividend of $0.55 which represents an annual dividend yield of 1.86%. See more information on Abbott Laboratories dividends here
What is Abbott Laboratories’s EPS estimate?
Abbott Laboratories’s EPS estimate is $1.2.
How many shares outstanding does Abbott Laboratories have?
Abbott Laboratories has 1,739,897,000 shares outstanding.
What happened to Abbott Laboratories’s price movement after its last earnings report?
Abbott Laboratories reported an EPS of $1.14 in its last earnings report, beating expectations of $1.105. Following the earnings report the stock price went down -4.692%.
Which hedge fund is a major shareholder of Abbott Laboratories?
Among the largest hedge funds holding Abbott Laboratories’s share is Fisher Asset Management LLC. It holds Abbott Laboratories’s shares valued at 1B.
---
Abbott Laboratories Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$129.06 (11.00% Upside)
$129.06 (11.00% Upside)
Blogger Sentiment
Bullish
GB:0Q15 Sentiment 96%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $16.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
30.98%
12-Months-Change
Fundamentals
Return on Equity
14.47%
Trailing 12-Months
Asset Growth
-0.46%
Trailing 12-Months
Company Description
Abbott Laboratories
Abbott Laboratories offers a diversified line of healthcare products. It operates through four reportable segments: Established Pharmaceutical Products International (includes international sales of branded generic pharmaceutical products), Nutritional Products Diagnostic Products and Medical Devices. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.
---
0Q15 Company Deck
---
0Q15 Earnings Call
Q2 2024
0:00 / 0:00
---
0Q15 Net sales Breakdown
42.10% Medical Devices
24.90% Diagnostic Products
20.33% Nutritional Products
12.63% Established Pharmaceutical Products
0.03% Other
---
0Q15 Stock 12 Month Forecast
Average Price Target
$129.06
▲(11.00% Upside)
Technical Analysis
Abbott Laboratories
―
Johnson & Johnson
―
Medtronic
―
Baxter International
―
Stryker
―
Best Analysts Covering 0Q15
1 Year
1 Year Success Rate
24/28 ratings generated profit
1 Year Average Return
+17.34%
reiterated a buy rating 3 months ago
Copying Rick Wise's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +17.34% per trade.
---